# Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function

> **NCT04469920** · PHASE1 · COMPLETED · sponsor: **Zydus Therapeutics Inc.** · enrollment: 98 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Saroglitazar Magnesium 2 mg
- **DRUG:** Saroglitazar Magnesium 4 mg

## Key facts

- **NCT ID:** NCT04469920
- **Lead sponsor:** Zydus Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-16
- **Primary completion:** 2022-03-21
- **Final completion:** 2022-03-21
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04469920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04469920, "Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04469920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*